MYO3B

Across TCGA pan-cancer cohorts, MYO3B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYO3B data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MYO3B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYO3B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where MYO3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.381	0.759	.013	7	view →
UCEC	OS	Tertile	III,IV	1.000	0.341	.034	4	view →
LUAD	OS	Median	II,III,IV	0.482	0.916	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MYO3B–CCRCC (OS)

Open the CCRCC breakdown →